---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Current treatment options and standard of care"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Current treatment options and standard of care. Covers Renin-Angiotensin system inhibitors and blood pressure control, Sodium-Glucose cotransporter-2 inhibitors, Nonsteroidal mineralocorticoid receptor antagonists, Glucocorticoids and calcineurin inhibitors, Dual endothelin angiotensin receptor antagonists, Antiretroviral therapy for HIV-associated nephropathy, and 3 further headings. 41 evidence topics quoted from 26 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/current-treatment-options-and-standard-of-care"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Current treatment options and standard of care

<a id="heading-2.2.2.1"></a>

## 2.2.2.1 Current Treatment Options and Standard of Care

- [Renin-Angiotensin system inhibitors and blood pressure control](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/renin-angiotensin-system-inhibitors-and-blood-pressure-control)

- [Sodium-Glucose cotransporter-2 inhibitors](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/sodium-glucose-cotransporter-2-inhibitors)

- [Nonsteroidal mineralocorticoid receptor antagonists](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/nonsteroidal-mineralocorticoid-receptor-antagonists)

- [Glucocorticoids and calcineurin inhibitors](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/glucocorticoids-and-calcineurin-inhibitors)

- [Dual endothelin angiotensin receptor antagonists](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/dual-endothelin-angiotensin-receptor-antagonists)

- [Antiretroviral therapy for HIV-associated nephropathy](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/antiretroviral-therapy-for-hiv-associated-nephropathy)

- [Dialysis](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/dialysis)

- [Kidney transplantation](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/kidney-transplantation)

- [Limitations of current therapies](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/limitations-of-current-therapies)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
